Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FORAO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AU2023308528A1 ADC2 (DAR of 4)
|
|||||
| Synonyms |
AU2023308528A1 ADC2 (DAR of 4)
Click to Show/Hide
|
|||||
| Organization |
PHEON THERAPEUTICS LTD
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
PBD-butanamide derivative
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
6-Maleimidocaproic acid
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
N- (4- ((S)-2- ((S)-2- (6- (2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3 methylbutanamido)propanamido)phenyl)-4- (4- (( (S)-2-methoxy-12-oxo-6a,7,8,9,10,12 hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepin-3-yl)oxy)butanamido)-1-methyl-1H pyrrole-2-carboxamide
|
|||||
ADC-specific functional property(2027 Update)
Binding Affinity
| Dissocation Constant (Kd) | Binding Target | Description | Reference |
|---|---|---|---|
| 0.635 nM |
huCDCP1 (F30-T667Q525)-8xHisT3
|
In vitro pharmacology was assessed in binding experiments of unconjugated mAb and ADCs to recombinant target antigen ECD. The target antigen was huCDCP1 (F30-T667Q525)-8xHisT3.
|
[1]
|